Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | PRCP | P42785 | 2/20 | 0.40 |
| ▸ | LHCGR | P22888 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4344858 | 0.81 | GID4 (0.60) | GID4L3MBTL1DRD3HTR2CPRCP | |
| SCHEMBL2358588 | 0.78 | GID4 (0.54) | GID4L3MBTL1MEN1KMT2ADRD3 | |
| SCHEMBL20912496 | 0.78 | MEN1 (0.50) | GID4L3MBTL1MEN1KMT2AHTR2A | |
| SCHEMBL20912502 | 0.78 | GID4 (0.71) | GID4L3MBTL1MEN1KMT2ADRD3 | |
| SCHEMBL20912489 | 0.78 | GID4 (0.71) | GID4L3MBTL1MEN1KMT2ADRD3 | |
| SCHEMBL2359018 | 0.78 | GID4 (0.71) | GID4L3MBTL1MEN1KMT2ADRD3 | |
| SCHEMBL12761088 | 0.77 | GID4 (0.52) | GID4L3MBTL1KMT2ADRD3PRCP | |
| SCHEMBL27928028 | 0.76 | PRCP (0.65) | GID4MEN1KMT2AHTR2AHTR2C | |
| SCHEMBL4339308 | 0.75 | GID4 (0.71) | GID4L3MBTL1DRD3HTR2AHTR2C | |
| SCHEMBL4344078 | 0.74 | GID4 (0.70) | GID4L3MBTL1DRD3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062776-A1 | HEDGEHOG ACYLTRANSFERASE INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-02-27 | — | — | US | disclosed |
| US-20200062776-A1 | HEDGEHOG ACYLTRANSFERASE INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-02-27 | — | — | US | disclosed |
| EP-3471723-A1 | HEDGEHOG ACYLTRANSFERASE INHIBITORS AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-2350093-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | GRUENENTHAL GMBH (DE) | 2012-10-03 | — | — | EP | disclosed |
| EP-2350093-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010046108-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2010-04-29 | — | — | WO | disclosed |
| US-20100105722-A1 | Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators | GRUENENTHAL GMBH (DE) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062776-A1 | HEDGEHOG ACYLTRANSFERASE INHIBITORS AND USES THEREOF | HHAT, SHH, MBOAT1 | GID4 1725/4885L3MBTL1 417/4885MEN1 2972/4885 |
| US-20100105722-A1 | Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators | KCNQ1, KCNQ3, KCNQ2 | GID4 2166/4885L3MBTL1 2790/4885MEN1 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.